Publicacións (34) Publicacións de Carlos Crespo Diz

2024

  1. Patient-reported outcome measures in severe asthma: an expert consensus

    Journal of Asthma, Vol. 61, Núm. 6, pp. 619-631

2023

  1. Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real World—MEMOGAL Study

    American Journal of Cardiovascular Drugs, Vol. 23, Núm. 5, pp. 583-593

  2. Efficacy and Safety of Inhaled Ethanol in Early-Stage SARS-CoV-2 Infection in Older Adults: A Phase II Randomized Clinical Trial

    Pharmaceutics, Vol. 15, Núm. 2

2022

  1. Development of a carbocysteine 10% + urea 5% cream for the topical treatment of congenital ichthyosis

    Farmacia Hospitalaria, Vol. 46, Núm. 2, pp. 51-56

  2. The economic burden of pulmonary arterial hypertension in Spain

    BMC Pulmonary Medicine, Vol. 22, Núm. 1

  3. Tratamiento de la eritrodisestesia palmoplantar con una fórmula magistral de urea 20% + triamcinolona acetónido 0, 2% + lidocaína 2%

    Ilaphal. Revista de la OFIL, Vol. 32, Núm. 3, pp. 301-303

2021

  1. Baricitinib and tofacitinib in patients with rheumatoid arthritis: results of regular clinical practice

    Farmacia Hospitalaria, Vol. 45, Núm. 4, pp. 165-169

  2. Development and characterization of inhaled ethanol as a novel pharmacological strategy currently evaluated in a phase ii clinical trial for early-stage sars-cov-2 infection

    Pharmaceutics, Vol. 13, Núm. 3

  3. Effectiveness, Safety, and Adherence to Treatment of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Real Practice

    Clinical Therapeutics, Vol. 43, Núm. 4, pp. e111-e121

  4. Efficacy of mepolizumab in usual clinical practice and characteristics of responders: Mepolizumab in usual clinical practice

    Respiratory Medicine, Vol. 187

  5. Safety and persistence of dimethyl fumarate as a treatment for relapsing-remitting multiple-sclerosis

    Farmacia Hospitalaria, Vol. 45, Núm. 2, pp. 73-76

2020

  1. Re-initiation of treatment with sargramostim in a patient with pulmonary alveolar proteinosis

    European Journal of Clinical Pharmacy, Vol. 22, Núm. 3, pp. 175-177

2018

  1. Anakinra for the treatment of undifferentiated systemic auto-inflammatory disease

    European Journal of Clinical Pharmacy, Vol. 20, Núm. 6, pp. 337-339

  2. Use of plasma exchange as therapeutic tool in clinical practice

    Farmacia Hospitalaria, Vol. 42, Núm. 1, pp. 16-19

  3. pH determination as a quality standard for the elaboration of oral liquid compounding formula

    Farmacia Hospitalaria, Vol. 42, Núm. 6, pp. 221-227

2017

  1. Adherence and safety study in patients on treatment with capecitabine

    Farmacia Hospitalaria, Vol. 41, Núm. 2, pp. 204-221

  2. Contralateral choroiditis secondary to combination therapy with simeprevir, sofosbuvir and ribavirin

    European Journal of Clinical Pharmacy, Vol. 19, Núm. 4, pp. 291-293

2016

  1. Dress syndrome secondary to simeprevir for the treatment of hepatitis C: A case report

    European Journal of Clinical Pharmacy, Vol. 18, Núm. 3, pp. 192-194

2014

  1. Adherence to oral antineoplastic therapy

    Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, Vol. 38, Núm. 6, pp. 475-481

  2. Algoritmo de diagnóstico y tratamiento del angioedema hereditario como herramienta para su manejo (Farmacia Hospitalaria (2013) 37, 6 (521-529))

    Farmacia Hospitalaria